---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041358"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:26:58.882476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Q2 net loss $15.8M; expects Phase 2 enrollment completion and Phase 3 start in Sep 2023

## Summary
- Net loss $15.8M for Q2 2023 vs $10.1M prior year; R&D expenses increased on clinical trial costs.
- Cash, cash equivalents and investments $95.3M at June 30, 2023, after ATM offering of 2.5M shares at $8.00.
- Phase 2 portion of pivotal epetraborole study for treatment-refractory MAC lung disease enrollment to finish in August; Phase 3 begins September.
- Top-line Phase 2 data expected summer 2024; over 90 active clinical sites across U.S., Japan, South Korea, Australia.

## SEC filing metadata
- accession: 0000950170-23-041358
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017023041358/0000950170-23-041358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017023041358/antx-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041358
- JSON: https://secwatch.observer/filing/0000950170-23-041358.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041358.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.8 million for the three months ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $15.8 million for the three months ended June 30, 2023
  - Result: reported results
  source text: AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017023041358/0000950170-23-041358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.